Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.63 better than the analyst estimate of $4.14. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.47 billion.

GUIDANCE:

Biogen sees FY2022 EPS of $16.50-$17.15, versus the consensus of $16.49. Biogen sees FY2022 revenue of $10-10.15 billion, versus the consensus of $10.01 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.